 MENLO PARK, Calif., Oct. 29, 2020 GLOBE NEWSWIRE -- CohBar, Inc. NASDAQ: CWBR, a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced it will host a Key Opinion Leader KOL webinar on the current treatment landscape in idiopathic pulmonary fibrosis IPF, the unmet medical need, and positive findings from preclinical studies of its CB5138 Analogs on Friday, November 6 at 2:00pm ET. 